Novogen Limited
140 Wicks Road
North Ryde
NSW 2113
Tel: 203-327-1188
Fax: 203-327-0011
125 articles about Novogen Limited
-
Novogen Release: GDC-0084 Progress Update: On Track For Phase II Commencement In 2017
8/22/2017
-
Novogen Restructures, Board to Take Pay Cuts
8/14/2017
-
Novogen Release: Progress Update On Cantrixil (TRXE-002-1) Development
8/7/2017
-
Novogen Terminates Preclinical Program, Will Cut an Undisclosed Number of Jobs
4/6/2017
-
C-Suite Shakeup: Novogen CEO North America, CSO and CFO Exit in Reorg
3/10/2017
-
Novogen Awarded Grant Of Up To A$3m By Australian Federal Government For Novel Drug Discovery Program
3/6/2017
-
Novogen Limited Acquires Privately-Held Neuro-Oncology Company To Support Development Of GDC-0084 In Glioblastoma
10/31/2016
-
Genentech Offloads Brain Drug to Tiny Australian Biotech Novogen for Bargain Price
10/31/2016
-
Novogen Limited Release: Conversion Of Convertible Notes
9/14/2016
-
Novogen Limited Release: US FDA Approves Investigational New Drug (IND) Application For Cantrixil(TM) (TRX-E-002-1) In Ovarian Cancer
9/12/2016
-
Novogen Limited Submits Investigational New Drug (IND) Application To The US FDA For Cantrixil In Ovarian Cancer
8/11/2016
-
Novogen Limited Patent Covering Anisina Has Proceeded To Grant
6/15/2016
-
Novogen Limited Provides Update On Development Of Cantrixil
5/2/2016
-
Novogen Limited Receives R&D Tax Incentive Cash Refund
3/17/2016
-
Novogen Limited Patent Covering Cantrixil And Trilexium Has Proceeded To Grant
2/19/2016
-
Novogen Limited Announces Changes To The Board With New Chairman And Deputy Chairman Appointed
2/5/2016
-
Novogen Limited Appoints Dr James Garner As Chief Executive Officer
12/10/2015
-
Novogen Limited Engages Contract Research Organisation To Conduct Cantrixil Phase 1 Clinical Trial
11/24/2015
-
Novogen Limited Patent Covering Cantrixil And Trilexium Accepted In Australia
11/12/2015
-
Novogen Limited Release: Preclinical Studies Justify Mode Of Delivery And Dosing Regimen For Anisina
11/11/2015